As of 2025-10-29, the Intrinsic Value of Rocket Pharmaceuticals Inc (RCKT) is -11.94 USD. This RCKT valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.97 USD, the upside of Rocket Pharmaceuticals Inc is -400.66%.
Based on its market price of 3.97 USD and our intrinsic valuation, Rocket Pharmaceuticals Inc (RCKT) is overvalued by 400.66%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.94 - -11.94 | -11.94 | -400.66% |
| P/E | (7.45) - (29.41) | (18.50) | -566.0% |
| DDM - Stable | (29.85) - (549.46) | (289.66) | -7396.1% |
| DDM - Multi | (28.81) - (422.18) | (54.48) | -1472.2% |
| Market Cap (mil) | 428.36 |
| Beta | 1.47 |
| Outstanding shares (mil) | 107.90 |
| Enterprise Value (mil) | 416.81 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.99% |
| Cost of Debt | 5.00% |
| WACC | 6.83% |